Kalexsyn
Distinguished Scientist
Kalexsyn Mar 2004 - Mar 2012
Senior Scientist
Pfizer 2000 - 2003
Senior Research Scientist
Education:
Western Michigan University 2007 - 2012
Master of Science, Masters, Accounting
Columbia University In the City of New York 1982 - 1983
Doctorates, Organic Chemistry
The Ohio State University 1977 - 1982
Doctorates, Doctor of Philosophy, Organic Chemistry
Clarion University of Pennsylvania 1973 - 1977
Bachelors, Bachelor of Arts, Chemistry
Skills:
Medicinal Chemistry Organic Synthesis Drug Design Organic Chemistry Synthetic Organic Chemistry Drug Discovery Lead Change Chemistry Parallel Synthesis Analytical Chemistry Hplc Nmr Structure Elucidation Nmr Spectroscopy Lc Ms Purification Chromatography Pharmaceutical Industry
Name / Title
Company / Classification
Phones & Addresses
Heinrich Schostarez Manager
Kalexsyn, Inc. Pharmaceuticals · Mfg Medicinal Chemicals
4502 Campus Dr, Kalamazoo, MI 49008 Michigan 2694888488
Scott D. Larsen - Kalamazoo MI Paul D. May - Richland MI John E. Bleasdale - Portage MI Charlotta Liljebris - Uppsala, SE Heinrich Josef Schostarez - Portage MI Tjeerd Barf - Uppsala, SE
Assignee:
Pharmacia Upjohn Company - Kalamazoo MI
International Classification:
C07C23722
US Classification:
514533, 514563, 560 41, 562450
Abstract:
The present invention comprises small molecular weight, non-peptidic inhibitors of formula I and II of Protein Tyrosine Phosphatase 1 (PTP1) which are useful for the treatment and/or prevention of Non-Insulin Dependent Diabetes Mellitus (NIDDM).
Scott D. Larsen - Kalamazoo MI 49009 Paul D. May - Richland MI 49083 John E. Bleasdale - Portage MI 49024 Charlotta Liljebris - S-74192 Knivsta, SE Heinrich Josef Schostarez - Portage MI 49024 Tjeerd Barf - S-753 34 Uppsala, SE Marianne Nilsson - SE-762 94 Rimbo, SE
The present invention comprises small molecular weight, non-peptidic inhibitors of formulae I-VII of Protein Tyrosine Phosphatase 1 (PTP1) which are useful for the treatment and/or prevention of Non-Insulin Dependent Diabetes Mellitus (NIDDM).
Statine Derivatives For The Treatment Of Alzheimer's Disease
Heinrich Josef Schostarez - Portage MI, US Robert Alan Chrusciel - Portage MI, US
Assignee:
Pharmacia & Upjohn, LLP - Kalamazoo MI
International Classification:
A61K031/165 C07C235/06
US Classification:
514617, 564152, 564153
Abstract:
The present invention relates to compounds of formula (I): useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
Aminediols For The Treatment Of Alzheimer's Disease
The present invention relates to compounds of formula (I): useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
Heinrich Schostarez - Portage MI, US Robert Alan Chrusciel - Portage MI, US Rebecca S. Centko - Portage MI, US
Assignee:
Pharmacia & UpJohn Company - Kalamazoo MI
International Classification:
C07D277/20
US Classification:
548195, 548190, 548193, 548194, 548196, 548200
Abstract:
Disclosed are compounds of formula: and pharmaceutically acceptable salts and esters thereof, useful in treating and/or preventing Alzheimer's disease and other similar diseases, wherein R, R, R, Rand Rare defined herein. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
Aminediols For The Treatment Of Alzheimer's Disease